1-Month Results From a Prospective Experience on CAS Using CGuard Stent System: The IRONGUARD 2 Study.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
28 09 2020
Historique:
received: 04 02 2020
revised: 08 05 2020
accepted: 12 05 2020
pubmed: 31 8 2020
medline: 28 7 2021
entrez: 31 8 2020
Statut: ppublish

Résumé

This study sought to evaluate 30-day safety and efficacy of dual-layer mesh-covered carotid stent systems for carotid artery stenting (CAS) in the clinical practice. When compared with carotid endarterectomy, CAS has been associated with a higher rate of post procedural neurologic events; these could be related to plaque's debris prolapsing through stent's mesh. Consequently, the need for increased plaque coverage has resulted in the development of dual-layer mesh-covered carotid stent systems. From January 2017 to June 2019, a physician-initiated, prospective, multispecialty registry enrolled 733 consecutive patients undergoing CAS using the CGuard embolic prevention system in 20 centers. The primary endpoint was stroke up to 30 days; secondary endpoints were technical and procedural success; external carotid artery occlusion; and in-hospital and 30-day transient ischemic attack (TIA), acute myocardial infarction (AMI), and death rates. Symptoms were present in 131 (17.87%) patients. An embolic protection device was used in 731 (99.72%) patients. Procedural success was 100%, technical success was obtained in all but 1 (99.86%) patient, who died in hospital due to a hemorrhagic stroke. Six TIAs, 2 minor strokes, and 1 AMI occurred during in-hospital stay, and external carotid artery occlusion was evident in 8 (1.09%) patients. Between hospital discharge and 30-day follow-up, 2 TIAs, 1 minor stroke, and 3 AMIs occurred. Therefore, the cumulative stroke rate was 0.54%. This real-world registry suggests that use of CGuard embolic prevention system in clinical practice is safe and associated with a minimal occurrence of adverse neurological events up to 30-day follow-up.

Sections du résumé

OBJECTIVES
This study sought to evaluate 30-day safety and efficacy of dual-layer mesh-covered carotid stent systems for carotid artery stenting (CAS) in the clinical practice.
BACKGROUND
When compared with carotid endarterectomy, CAS has been associated with a higher rate of post procedural neurologic events; these could be related to plaque's debris prolapsing through stent's mesh. Consequently, the need for increased plaque coverage has resulted in the development of dual-layer mesh-covered carotid stent systems.
METHODS
From January 2017 to June 2019, a physician-initiated, prospective, multispecialty registry enrolled 733 consecutive patients undergoing CAS using the CGuard embolic prevention system in 20 centers. The primary endpoint was stroke up to 30 days; secondary endpoints were technical and procedural success; external carotid artery occlusion; and in-hospital and 30-day transient ischemic attack (TIA), acute myocardial infarction (AMI), and death rates.
RESULTS
Symptoms were present in 131 (17.87%) patients. An embolic protection device was used in 731 (99.72%) patients. Procedural success was 100%, technical success was obtained in all but 1 (99.86%) patient, who died in hospital due to a hemorrhagic stroke. Six TIAs, 2 minor strokes, and 1 AMI occurred during in-hospital stay, and external carotid artery occlusion was evident in 8 (1.09%) patients. Between hospital discharge and 30-day follow-up, 2 TIAs, 1 minor stroke, and 3 AMIs occurred. Therefore, the cumulative stroke rate was 0.54%.
CONCLUSIONS
This real-world registry suggests that use of CGuard embolic prevention system in clinical practice is safe and associated with a minimal occurrence of adverse neurological events up to 30-day follow-up.

Identifiants

pubmed: 32861633
pii: S1936-8798(20)31174-2
doi: 10.1016/j.jcin.2020.05.026
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2170-2177

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Pasqualino Sirignano (P)

Vascular and Endovascular Surgery Unit, Department of Surgery Paride Stefanini, Sapienza University of Rome, Rome, Italy. Electronic address: pasqualino.sirignano@uniroma1.it.

Eugenio Stabile (E)

Division of Cardiology, Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Wassim Mansour (W)

Vascular and Endovascular Surgery Unit, Department of Surgery Paride Stefanini, Sapienza University of Rome, Rome, Italy.

Laura Capoccia (L)

Vascular and Endovascular Surgery Unit, Department of Surgery Paride Stefanini, Sapienza University of Rome, Rome, Italy.

Federico Faccenna (F)

Vascular and Endovascular Surgery Unit, Department of Surgery Paride Stefanini, Sapienza University of Rome, Rome, Italy.

Francesco Intrieri (F)

Unit of Vascular and Endovascular Surgery, Annunziata Hospital, Cosenza, Italy.

Michelangelo Ferri (M)

Vascular and Endovascular Surgery Unit, Mauriziano Umberto I Hospital, Turin, Italy.

Salvatore Saccà (S)

Division of Cardiology, Mirano Public Hospital, Mirano, Italy.

Massimo Sponza (M)

Division of Vascular and Interventional Radiology, Udine University Hospital, Udine, Italy.

Paolo Mortola (P)

Department of Vascular and Endovascular Surgery, Galliera Hospital, Genoa, Italy.

Sonia Ronchey (S)

Unit of Vascular Surgery, Cardiovascular Thoracic Department, S. Filippo Neri Hospital, Rome, Italy.

Placido Grillo (P)

Division of Cardiology, Sant'Anna Hospital, Catanzaro, Italy.

Roberto Chiappa (R)

Department of Vascular and Endovascular Surgery, S. Pertini Hospital, Rome, Italy.

Sergio Losa (S)

Cardiovascular Department, MultiMedica IRCCS Scientific Institute, Milan, Italy.

Francesco Setacci (F)

Cardiovascular Department, MultiMedica IRCCS Scientific Institute, Milan, Italy.

Stefano Pirrelli (S)

Division of Vascular Surgery, San Carlo Poma Hospital, Mantova, Italy.

Maurizio Taurino (M)

Unit of Vascular Surgery, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.

Maria Antonella Ruffino (MA)

Department of Diagnostic Imaging and Radiotherapy - Vascular Radiology, Città della Salute e della Scienza di Torino, Turin, Italy.

Marco Udini (M)

Vascular Surgery, Moriggia Pelascini Hospital, Gravedona, Italy.

Domenico Palombo (D)

Vascular and Endovascular Surgery Unit, IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy.

Arnaldo Ippoliti (A)

Vascular Surgery Unit, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Nunzio Montelione (N)

Vascular Surgery, University of Campus Biomedico of Rome, Italy.

Carlo Setacci (C)

Vascular and Endovascular Surgery Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.

Gianmarco de Donato (G)

Vascular and Endovascular Surgery Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.

Massimo Ruggeri (M)

Vascular Surgery, San Camillo de Lellis Hopital, Rieti, Italy.

Francesco Speziale (F)

Vascular and Endovascular Surgery Unit, Department of Surgery Paride Stefanini, Sapienza University of Rome, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH